At a glance
ClinicalIndex Comparison RecordN/ACompleted· 99 enrolled
Drug / intervention
Linezoliddrug
Likely dose
Linezolid 600mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Post Marketing Surveillance on the Efficacy, Safety and Tolerability of Linezolid (Zyvox) in the Treatment of Gram Positive Infections
In Brief
An observational study evaluating Linezolid for Gram-Positive Bacterial Infections. Completed, enrolled 99 participants.
Detailed Summary
The purpose of this study is to determine if Linezolid is safe for adult Filipino patients diagnosed with gram positive infections.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsGram-Positive Bacterial Infections
Countries--
Collaborators--
Timeline
N/ACompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2004
Primary CompletionMar 2005
First PostedMar 2012
TodayJul 2026
First PostedMar 28, 2012
Enrollment StartFeb 1, 2004
Primary CompletionMar 1, 2005
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 14.3 years ago
Interventions
Linezoliddrug
1. Vancomycin-resistant, E. faecium, including concurrent bacteremia: Linezolid for 600mg (IV or oral) every 12 hours for 14-28 days 2. Nosocomial infection, cSSTI: Linezolid for 600mg (IV or oral) every 12 hours for 10-14 days 3. Uncomplicated SSTI: Linezolid for 400mg oral every 12 hours for 10-14 days